Release 6.5

02 December 2019 by Cambia Staff in Featured, Release Notes

Release 6.5
New EPO sequence data, PatSeq bulk download options, New users section and more!

New EPO sequence data, PatSeq bulk download options, New users section and more!

N.B. We are no longer supporting Internet Explorer, all other modern and standards compliant browsers are still supported (e.g. Firefox, Microsoft Edge, Chrome, Safari, Opera).

We are pleased to announce that the Lens team has now parsed, harmonized and integrated the back file sequence listings data (1989-March 2012) from EP, Euro-PCT and PCT publications wherein EPO is the international Searching Authority enriching the Lens PatSeq data by an additional 10.7 million nucleotide and amino acid sequences, bringing the total data content to over 340 million sequences.

With this release, the Lens offers a wider range of PatSeq bulk data products for academic use in research and publications and for commercial uses. Please see a full description of the products here, select the product that best suits your needs from the PatSeq tab in the API & Data page and check the PatSeq Bulk Download Terms of Use before you place your order.


  • The following new PatSeq bulk download options are now available:
    • Free - the patent sequences mapped on the human genome (FASTA format),
    • Rich data format which is a custom file format based on EMBL but modified to accommodate rich patent metadata. Below is a list of sequence and patent metadata fields that is offered in the Rich data format:
      • Sequence type
      • Sequence size
      • Sequence ID number (SEQ ID NO)
      • Claim location including claim number
      • Corresponding patent filing and publication numbers
      • Declared species
      • Patent jurisdiction
      • Patent title
      • Dates (priorities, filing, publication)
      • Inventors
      • Applicants / assignees (for US)
      • Priority documents
  • The PatSeq Landing Page has been upgraded and rendered consistent with the other Lens pages.
  • We have also added a new section on the landing page about “What Users’ asked this month” to respond to many of you who are engaging with the platform and are curious to know a bit more about the Lens capabilities.  Check it out and let us know if you want to see more of these questions.
  • We have shared a new working paper on the Lens metarecord concept and how the Lens is using it along the Lens ID to manage the complexity of scholarly and patent data.  We welcome your comments on it as well.

Additional minor changes (user feedback):

  • Add assignee / owner field to patent export
  • Added HTML formatting of saved query alert emails


  • Fix sorting when expanding by family
  • Fix error when removing all items from a collection
  • Fix word size in PatSeq Finder search parameter panel
  • Fix edit search text parsing for patent searches with "AND" within the search terms
  • Fix the "Documents citing" link in patent citations tab

API & Data Improvements:

Interested in helping us improve?

Become a Lens partner!  Find out what features or Lens functionality would make your work more effective and partner with the Lens to make it happen.  We are pleased to introduce a new Lens partner, Prof. Chaomei Chen of CiteSpace.  Prof. Chen is currently working on a Lens integration for the application, which will allow CiteSpace users to use their own Lens scholarly API access tokens in the app to create network visualisations from Lens data via the API.  We are also grateful to several patent examiners and analysts who have advised us and sent valuable feedback as we transition to the new patent data store and enrich it with more metadata. You now have a similar opportunity to contribute to this public good resource.

For guidance on navigating the Scholarly API, please check the online documentation, and to report bugs/issues, usability related questions, or to request features, please use our GitHub issue tracker. For general questions, please visit our Support Center to check out the latest tutorials or contact us at with your questions or comments.